期刊文献+

姜黄素逆转肝癌耐药性实验研究 被引量:9

Reversion of drug resistance in a hepatocellular carcinoma by curcumine in vitro
下载PDF
导出
摘要 目的研究姜黄素对人肝细胞癌耐药株HepG2/ADM耐药逆转作用,并初步探讨其逆转机制。方法通过培养液阿霉素浓度梯度递增法建立HepG2/ADM细胞株,采用MTT法检测其耐药性,免疫组化法检测HepG2/ADM与亲本株P-gp的表达。采用姜黄素作用于HepG2/ADM细胞,MTT法测定其逆转倍数,高效液相色谱法(HPLC)测定细胞内ADM含量。结果HepG2/ADM细胞表现出多药耐药性,P-gp的表达较亲本细胞明显增多,加用姜黄素后HepG2/ADM细胞耐药性有明显逆转,细胞内ADM浓度明显升高。结论姜黄素可以逆转HepG2/ADM细胞的耐药性,提高该细胞对化疗的敏感度,其逆转机制可能与降低P-gp对药物的外排功能,增加细胞内药物浓度有关。 [ Objective ] To evaluate reversal effects of curcumin on HepG2/ADM, multidrug-resistant human hepatoeareinoma cell line, and explore its reversal mechanism. [Methods] HepG2/ADM ceil line was established through increasing ADM with concentration gradient method. The cell viability was determined by MTF. Immunohis- tochemistry was used to detect expression of HepG2/ADM and parents. The effects of eureumin at different concentration on HepG2/ADM cells were observed by microscope and detected by MTT. High performance liquid chro- matography (HPLC) was used to detect concentration of ADM in cells. [Results] HepG2/ADM cell line was estab- lished, which muhi-drug resistance is related to over-expression of P-gp. Increased ceil apoptosis and decreased cell viability followed by treatment of cureumin, which resulted from aceumulation of ADM in HepG2/ADM ceils. [Conclusion] Cureumin can reverse muhidrug resistance of HepG2/ADM cells through inhibiting P-gp-mediated drug efflux and subsequently increased accumulation of drugs.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2008年第17期2441-2443,2448,共4页 China Journal of Modern Medicine
关键词 姜黄素 肝癌 多药耐药 cureumin hepatocarcinoma MDR
  • 相关文献

参考文献1

二级参考文献15

  • 1BOLDRINI L, FAVIANA P, GISFREDI S, et al. Identification of FAS (APO-1/CD95)and p53 gene mutations in non-small cell lungcancer[J]. Inter Oncol, 2002, 20(1): 155-159.
  • 2THOMPSON CB. Apoptosin the pathogenesis and treatment of disease[J]. Science, 1995, 267: 145-153.
  • 3WANG Q, BECK WT. Transcriptional suppression of muhidrug resistance-associatal protein (MRP) gene expression by wild-type p53[J]. Cancer Res, 1998, 58: 5762-5769.
  • 4SULLIVAN GF, YANG JM, VASSIL A, et al. Regulation of expression of the multidrugcells.resistance protein MRP1 by p53 in human prostate cancer[J]. J Clin Invest, 2004, 105: 1261-1267.
  • 5TAKAYAMA K, NAKANISHI Y, HARA N. Gene therapy for lung cancer treatment[J]. Nippon Rinsh, 2000, 58(2): 1048-1057.
  • 6LEVINE AJ. p63, the cellular gatekeeper for growth and division [J]. Cell, 1997, 88: 323-338.
  • 7WICK W, WELLER M. Modulation of MDR/MRP by wild-type and mutant Bahr p53[J]. J In Invest, 2001, 107: 643-646.
  • 8TOSCHI B, ROTA R, ANTONINI A, et al. Wild-Type p53 gene transfer inhibits invasion and reduces matrix metal.loproteinase-2 levels in p53-mutated human melanoma cells[J]. Invest Dermatol,2000, 114: 1188-1194.
  • 9TADAHISA S, PHILIP JT, TIMOTHY SS, et al. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glimna comeates with site-specific phosphorylation [J]. Cancer Res,2002, 62:1069-1176.
  • 10ENGELHARDT JF, YE X, DORANZ B, et al. Ablation of E/A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver[J]. Proc Natl Acad Sci, 1994, 91: 6196-6200.

共引文献4

同被引文献118

引证文献9

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部